drugset / Trial / NCT05355051
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.
Timeline
- Start
- 2022-10-05
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacytidine | Other / unclassified | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |